1. Home
  2. ZURA vs CMDB Comparison

ZURA vs CMDB Comparison

Compare ZURA & CMDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zura Bio Limited

ZURA

Zura Bio Limited

HOLD

Current Price

$4.45

Market Cap

455.4M

Sector

Health Care

ML Signal

HOLD

Logo Costamare Bulkers Holdings Limited

CMDB

Costamare Bulkers Holdings Limited

HOLD

Current Price

$23.80

Market Cap

453.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZURA
CMDB
Founded
2022
2023
Country
United States
Monaco
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
455.4M
453.8M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
ZURA
CMDB
Price
$4.45
$23.80
Analyst Decision
Buy
Analyst Count
6
0
Target Price
$13.00
N/A
AVG Volume (30 Days)
1.7M
61.3K
Earning Date
05-14-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.00
$11.70
52 Week High
$7.25
$24.76

Technical Indicators

Market Signals
Indicator
ZURA
CMDB
Relative Strength Index (RSI) 30.44 65.70
Support Level $4.22 $16.35
Resistance Level $5.94 $24.76
Average True Range (ATR) 0.37 1.13
MACD -0.17 0.07
Stochastic Oscillator 4.03 81.07

Price Performance

Historical Comparison
ZURA
CMDB

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

About CMDB Costamare Bulkers Holdings Limited

Costamare Bulkers Holdings Ltd is an international owner and operator of dry bulk vessels providing transportation of dry bulk commodities globally for a broad range of customers. Its vessels transport a broad range of bulks, such as iron ore, coal and grains and minor bulks, such as bauxite, phosphate fertilizers and steel products, across shipping routes globally. The company's vessel fleet includes Current Dry Bulk Fleet, Chartered-In Vessels Fleet, and Chartered-In Newbuilding Vessels. It operates under one reportable segment, that of operating dry bulk vessels.

Share on Social Networks: